Search company, investor...
Kiromic company logo

Kiromic

kiromic.com

Founded Year

2006

Stage

IPO | IPO

Total Raised

$130K

Date of IPO

10/16/2020

Market Cap

0.00B

Stock Price

0.20

About Kiromic

Kiromic (NASDAQ: KRBP) exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. The company's cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.

Headquarters Location

7707 Fannin Suite 140

Houston, Texas, 77054,

United States

832-968-4888

Missing: Kiromic's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kiromic's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kiromic

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kiromic is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Kiromic Patents

Kiromic has filed 9 patents.

The 3 most popular patent topics include:

  • Cancer treatments
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/13/2017

7/21/2020

Clusters of differentiation, Transcription factors, Experimental cancer drugs, Antineoplastic drugs, Lymphoma

Grant

Application Date

3/13/2017

Grant Date

7/21/2020

Title

Related Topics

Clusters of differentiation, Transcription factors, Experimental cancer drugs, Antineoplastic drugs, Lymphoma

Status

Grant

Latest Kiromic News

Kiromic BioPharma : Corporate Presentation

Nov 21, 2022

Message : Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. Kiromic makes such forward- looking statements pursuant to the safe harbor provisions of the United States Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as: "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding: Kiromic's current and anticipated IND applications including statements regarding the scope of and timing for submission of an IND application; the Deltacel™ product platform; the sponsored research agreement and the data that will be generated as a result of such collaboration; the timing for submitting and activating Kiromic's IND applications; the benefits of utilizing non-genetically engineered Gamma Delta T cells as our first in-human study; Kiromic's ability to achieve its objectives; and the timing for the initiation and successful completion of Kiromic's clinical trials of its product candidates. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in our Annual Report on Form 10-K for the year ended December 31, 2021, and as detailed from time to time in our SEC filings. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Such forward-looking statements relate only to events as of the date of this press release. We undertake no obligation to update any forward-looking statements except to the extent required by law. PAGE

Kiromic Frequently Asked Questions (FAQ)

  • When was Kiromic founded?

    Kiromic was founded in 2006.

  • Where is Kiromic's headquarters?

    Kiromic's headquarters is located at 7707 Fannin, Houston.

  • What is Kiromic's latest funding round?

    Kiromic's latest funding round is IPO.

  • How much did Kiromic raise?

    Kiromic raised a total of $130K.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.